Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer

Clinical trial NCT03377101 · WITHDRAWN

Trial details

NCT number: NCT03377101
Sponsor: National Cancer Institute (NCI)
Status: WITHDRAWN
Phase: Phase 2
Study type: INTERVENTIONAL

Estrogen Receptor Positive HER2/Neu Negative Progesterone Receptor Positive Stage IV Breast Cancer AJCC v6 and v7

Start date: 2018-08-07
Primary completion: 2018-08-07
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.